TransCan Genomics (TCG) is a clinical genomics and data-infrastructure company dedicated to supporting healthcare systems worldwide through a public-private collaboration model. We deliver an integrated platform that combines clinical-grade testing, centralized genomic data systems, and advanced automation tools designed to help clinicians, laboratories, and health systems scale efficiently while maintaining control of their data. Across the globe, demand for genetic testing is rapidly growing, yet many healthcare systems struggle with limited analysis capacity, fragmented data infrastructure, and dependence on external commercial labs. TCG solves this by partnering with domestic accredited sequencing facilities and providing downstream technology layers to transforms raw sequencing into high-quality clinical results, unified data repositories, and real-time clinical decision tools. Our platform streamlines workflows end-to-end, from test ordering to report generation, and supports national genomic initiatives through secure, open, high-value data infrastructure. TCG's proprietary data management architecture supports genetic data residency, provides enhanced clinical insights, and streamlines charting workflows - enabling clinicians to spend more time on patient care with consistent, actionable outputs. Health systems benefit from scalable digital infrastructure, lower operating costs, and the ability to retain genomic data as a strategic national asset, while participating partner laboratories gain new revenue opportunities. Our customers include medical genetics clinics, regional health systems, public genomic programs, and research organizations seeking reliable, scalable, and data-secure clinical genomics solutions. With a first-mover advantage in public-sector partnerships and a model built for global expansion, TCG is positioned to become a leading service provider in a multi-billion-dollar international diagnostic genomic testing market.